The aim of the collaboration---which marks the first time Invitrogen has stepped directly into the field of diagnostics--is to develop new diagnostic and prognostic tests for cancer and general laboratory medicine.
In the deal, Invitrogen will provide research tools, which include human protein microarrays, engineered cell lines, cell-based assays, and cloning and expression technologies. The Mayo Clinic will contribute patient samples and expertise in diagnostic assays. Invitrogen can license technologies resulting from the collaboration either exclusively or non-exclusively, in exchange for funding several biomarker research programs at Mayo.
"Our objective with this agreement is to generate new enabling technologies for doctors, patients and the larger health-care community," Invitrogen CEO Greg Lucier said in a statement.